BioSpace News Archive

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), today announced the continuing success of PolyTope® TATX-03 antibody combination therapy to neutralize variants of concern of the COVID-19 causative virus, including the latest Omicron BA.5 subvariant, validated by an independent research organization in an authentic virus assay.

Neuronetics, Inc. (NASDAQ: STIM), announced today that they have received 510(k) clearance for their D-Tect™ MT Accessory, which is the latest innovation in NeuroStar’s commitment to simplify the motor threshold determination for physicians.

Galecto, Inc. (NASDAQ: GLTO), today announced a recent publication in the Journal of Cancer Research and Clinical Oncology,1 a peer-reviewed scientific journal, supporting the Company’s ongoing clinical programs by reinforcing the foundational galectin-3 biology underlying Galecto’s approach to the inhibition of galectin-3 for the treatment of cancer.

AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ AVCR ”) is pleased to provide this corporate update on the Company’s Q2 results.

ALR Technologies SG Pte. Ltd, the diabetes management company, announces a distribution agreement with a global leader in animal health is now anticipated to be complete in September.

Theranica today announced the closing of its Series C funding round, with a first closing of $45 million.

SQI Diagnostics Inc. today reported its financial and operational results for the third quarter for fiscal year ending September 30, 2022.

Thermo Fisher Scientific Inc., the world leader in serving science, is showcasing a new mass spectrometry instrument and consumables that enable biopharmaceutical and proteomics customers to drive scientific breakthroughs and solve analytical challenges.

Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce new data to be presented across its oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2022.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced that the first patient has been dosed in the Phase 1/2 study evaluating [225Ac]-FPI-1966 (FPI-1966) in patients with advanced solid tumors expressing fibroblast growth factor receptor three (FGFR3).